Russian scientists are exploring the use of bacteria for targeted drug delivery

22 August 2018

GMP News

Russian physicists will be able to control the movement of bacteria for the treatment of cardiovascular diseases. For this purpose in collaboration with microbiologists, they established a laboratory at the Moscow Institute of Physics and Technology, according to information from the Joint Institute for High Temperatures (JIHT) of the Russian Academy of Sciences.

“JIHT opens at Moscow Institute of Physics and Technology (MIPT) the laboratory of active media and systems in collaboration with the Gamaleya Research Institute of Epidemiology and Microbiology. In interaction with microbiologists JIHT scientists plan to set up experiments with bacterial cultures that behave like active particles in some settings,” the report says.

As scientists have explained, in medicine, research in the field of active particles is associated with the possibility of targeted drug delivery – for example to the tumor area for its subsequent irradiation. Active particles can also eliminate atherosclerotic plaques that build up in the walls of blood vessels.

“We are talking about the use and transformation of energy from an external source into the energy of motion: if we control this mechanism, then we control the motion of the particles and can make them move in a required direction – for example, along blood vessels under control of magnetic field or particles with magnetic properties,” commented Oleg Petrovdirector of theJIHT RAS.

In his opinion, the work of the laboratory will bring to a new level both interdisciplinary research at the intersection of physics and microbiology, and interdepartmental interaction in new scientific fields.


Previous publication Next publication

Media Center

  • 31 October 2018

    Scientists unveiled a more effective approach for assessing drug response

    Scientists from Eli Lilly and Company, the Icahn School of Medicine at Mount Sinai (New York, USA) and Sema4 (Stamford, USA) released results from a proof-of-concept study demonstrating that patient-derived cells offer a more effective approach for assessing drug response than conventional methods.

  • 30 October 2018

    Researchers developed an AI approach to identify antibiotic resistance genes

    Researchers at the University of California San Diego (USA) have developed an approach that uses machine learning to identify and predict which genes make infectious bacteria resistant to antibiotics. The approach was tested on strains of Mycobacterium tuberculosis – the bacteria that cause tuberculosis (TB) in humans. It identified 33 known and 24 new antibiotic resistance genes in these bacteria.

  • 29 October 2018

    Expanding the reach of gene editing with a new CRISPR enzyme

    The CRISPR-Cas9 gene editing system has been widely studied because of its potential therapeutic applications, but limitations in the number of locations on the genome it can target remain a major drawback. Now scientists at the Massachusetts Institute of Technology have identified a new Cas9 enzyme that they say can help CRISPR reach more gene mutations.

  • 26 October 2018

    Biotech Backed by Bain, Pfizer loads prime CNS assets into new biotech

    Pfizer has followed through on its pledge to divest a hunk of its neuroscience R&D, spinning several programs into a new company called Cerevel Therapeutics backed by $350 million in venture funding. Pfizer is contributing a trio of clinical-stage drug candidates—including a Parkinson’s therapy due to start phase 3 testing next year—plus a clutch of earlier-stage programs, while Bain Capital and affiliates stumped up the initial funding.

Read more